Hutchison MediTech Begins Phase II Study of Its PSC Drug Savolitinib in China

Hutchison China MediTech (Chi-Med) and AstraZeneca have launched a Phase II study in China of savolitinib (HMPL-504/AZD6094/volitinib), an oral inhibitor targeting c-Met receptor tyrosine kinase for treatment of locally advanced or metastatic pulmonary sarcomatoid carcinoma (PSC). The first drug dose was administered on February 10, 2017. More details.... Stock Symbols (AIM/Nasdaq: HCM )  (LON/NYSE: AZN ) Share this with colleagues: // //